Fred Martin
Disciplined Growth Investors
Fred Martin Coherus BioSciences Inc stake
total: 241
Disciplined Growth Investors CHRS trades
- Total transactions:
- 18
- New positions:
- 1
- Sold out:
- 1
- Added:
- 10
- Reduced:
- 6
- Held since:
- 2020 Q3
- Held for:
- 18 quarters
- Latest activity:
- 2025 Q1
According to 2026 Q2 report, Fred Martin doesn't hold any Coherus BioSciences Inc (CHRS) shares. To date, the estimated cost basis is nearly $11.87 for "buy" trades and estimated average "sell" price is $3.9. Disciplined Growth Investors first purchased CHRS in 2020 Q3, initially acquiring 472,214 shares. Since the initial investment in Coherus BioSciences Inc (CHRS), Disciplined Growth Investors has made 17 more transactions.
When did Fred Martin sell Coherus BioSciences Inc (CHRS)?
Fred Martin sold off the entire Coherus BioSciences Inc (CHRS) position in 2025 Q1.
When did Fred Martin buy Coherus BioSciences Inc (CHRS)?
Fred Martin first invested in Coherus BioSciences Inc (CHRS) in 2020 Q3 at the reported quarter-end price of $18.34 per share.
What's the cost basis of Disciplined Growth Investors's CHRS stake?
The estimated cost basis for Coherus BioSciences Inc (CHRS) stake is around $11.87 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $11.86
- Weighted AVG sell price:
- $3.90
Fred Martin's historical trades in Coherus BioSciences Inc
18 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$1.38
|
|
-100% (-566,746)
|
-0.01%
|
|
2024 Q4
|
0.01%
|
566,746
|
$1.38
|
$782,109
|
-26.04% (-199,562)
|
-0.01%
|
|
2024 Q3
|
0.02%
|
766,308
|
$1.04
|
$796,960
|
-39.04% (-490,781)
|
-0.01%
|
|
2024 Q2
|
0.04%
|
1,257,089
|
$1.73
|
$2,174,764
|
+0.09% (+1,152)
|
+0%
|
|
2024 Q1
|
0.05%
|
1,255,937
|
$2.39
|
$3,001,689
|
+7.65% (+89,210)
|
+0%
|
|
2023 Q4
|
0.08%
|
1,166,727
|
$3.33
|
$3,885,201
|
-1.43% (-16,899)
|
-0%
|
|
2023 Q3
|
0.11%
|
1,183,626
|
$3.74
|
$4,426,761
|
+0.33% (+3,941)
|
+0%
|
|
2023 Q2
|
0.11%
|
1,179,685
|
$4.27
|
$5,037,255
|
+1.22% (+14,173)
|
+0%
|
|
2023 Q1
|
0.20%
|
1,165,512
|
$6.84
|
$7,972,102
|
+1.93% (+22,092)
|
+0%
|
|
2022 Q4
|
0.23%
|
1,143,420
|
$7.92
|
$9,055,886
|
+1.00% (+11,324)
|
+0%
|
|
2022 Q3
|
0.30%
|
$9.61
|
+360.16% (+886,075)
|
|||
|
2022 Q2
|
0.05%
|
$7.24
|
+0.45% (+1,100)
|
|||
|
2022 Q1
|
0.07%
|
$12.91
|
+3.75% (+8,855)
|
|||
|
2021 Q4
|
0.08%
|
$15.96
|
-48.05% (-218,358)
|
|||
|
2021 Q2
|
0.12%
|
$13.83
|
+11.15% (+45,581)
|
|||
|
2021 Q1
|
0.12%
|
$14.61
|
-10.82% (-49,600)
|
|||
|
2020 Q4
|
0.15%
|
$17.38
|
-2.92% (-13,771)
|
|||
|
2020 Q3
|
0.20%
|
$18.34
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.